ClinicaliQ Trial Snapshot
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) — Active Not Recruiting • Phase I • Oncology • NCT04170153.
- Early-stage study testing a new cancer drug (tuvusertib) alone and combined with niraparib in advanced solid tumors to assess safety and effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib. Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors Interventions: M1774, Niraparib Lead Sponsor: EMD Serono Research & Development Institute, Inc. Planned Enrollment: 161 participants